Peru Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Peru Pharmaceuticals & Healthcare Report

The Peru Pharmaceuticals and Healthcare Report

Independent 5-year pharmaceutical and healthcare industry forecasts for Peru.

Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Peruvian pharmaceutical and healthcare industry.

Competitive intelligence, Peruvian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Peruvian market.

The Peru Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.

Business Monitor International’s Peru Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Peruvian pharmaceutical and healthcare industry.

Key Benefits of Report

Coverage

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.

Market Summary

Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.

Regulatory Regime

Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.

BMI 5-Year Industry Forecast

5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

BMI 5-Year Macroeconomic Forecasts

BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt

Competitive Landscape & Profiles

Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.

Peru Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Table of Contents

Chapter - Executive Summary

Peru: Pharmaceuticals And Healthcare Industry SWOT
Peru Political SWOT Analysis
Peru Economic SWOT Analysis
Peru Business Environment SWOT Analysis

Chapter - Pharmaceutical Business Environment Ratings

Limits Of Potential Returns
Risks To Realisation Of Returns

Chapter - Peru Market Summary

Regulatory Regime
Intellectual Property Regime
Trade Agreements
Counterfeit Pharmaceuticals
Pricing Regime
Government Tenders
Reimbursement Regime
Other Regulatory Issues

Chapter - Industry Developments

Epidemiology
Healthcare Sector
Healthcare Provision
Health Insurance
Pharmaceutical Sector
Recent Company Activity
Pharmaceutical Distribution And Retail
Clinical Trials
Medical Devices

Chapter - Industry Forecast Scenario

Table: Peru – Drug Market Indicators, Historical Data and Forecasts
Key Growth Factors – Industry
Table: Peru – Health Expenditure Indicators, Historical Data and Forecasts
Key Growth Factors – Macroeconomic
Table: Peru – Economic Activity
Prescription Market Forecast
Table: Peru – Prescription Drug Market Indicators, Historical Data and Forecasts (PENmn unless otherwise indicated)
Patented Market Forecast
Table: Peru - Patented Market Indicators, Historical Data and Forecasts
Generics Market Forecast
Table: Peru – Generic Market Indicators, Historical Data and Forecasts
OTC Market Forecast
Table: Peru – OTC Market Indicators, Historical Data and Forecasts (PENmn unless otherwise stated)
Pharmaceutical Trade Forecasts
Table: Peru – Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn)
Medical Devices Forecasts
Table: Peru - Medical Device Market Indicators, Historical Data and Forecasts (US$mn unless otherwise indicated)
Other Healthcare Data Forecasts
Table: Peru - Other Healthcare Data Indicators, Historical Data and Forecasts
Key Risks To BMI's Forecast Scenario

Chapter - Competitive Landscape

Table: Peruvian Pharmaceutical Companies That Acquired GMP Accreditation In 2006

Chapter - Company Profiles

Leading Multinationals
Sanofi-Aventis
Merck & Co
GlaxoSmithKline
Novartis
Pfizer
AstraZeneca
Indigenous Manufacturer Profiles
Farmaindustria
Unimed
Hersil

Chapter - Country Snapshot: Peru Demographic Data

Section 1: Population
Section 2: Education And Healthcare
Section 3: Labour Market And Spending Power

Chapter - BMI Forecast Modelling

How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Peru Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Executive Summary

In BMI’s updated Business Environment Rankings (BER) for Q209, Peru remained second-bottom in the matrix assessing ten major markets in the Americas. A small market size and a deficient intellectual property (IP) environment – including the tolerance for non-bioequivalent similares and widespread counterfeiting - represent some of the major drawbacks to the involvement of foreign companies. Nevertheless, Peru offers considerable longer-term benefits to foreign companies, not least due to its rising population numbers and solid GDP growth in recent years. A recently ratified trade agreement with the US is expected to be enforced in the course of 2009, thus leading to improvements in the intellectual property (IP) regime, but also to more intense competition to local players. In order to address such changes, local pharmaceutical manufacturers’ association announced that it plans to invest US$15mn in manufacturing and research processes in the course of 2009.

However, downward pressure on prices – largely a factor of the strong competition in the chain-dominated pharmacy retail sector and the government’s continuing support for copy and generic medicines - is likely to lead to Peru’s pharmaceutical market posting a modest compound annual growth rate (CAGR) of 6.04% in local currency terms through to 2013, though this envisages the strengthening of local currency. In 2013, the market value should reach PEN3.64bn (US$1.35bn) at consumer prices, rising from PEN2.72bn (US$0.885bn) in 2008.

In the meantime, Peru has been recording improvements in child and maternal health indicators, local press reported in February 2009 that the most recent edition of the UNICEF’s The State of the World’s Children noted that Peru has made considerable progress in reducing child and maternal deaths. According to UNICEF, childhood under-five mortality fell by 74% in the period between 1990 and 2007, although maternal mortality is still among the highest in the region. Consequently, the Ministry of Health and UNICEF-Peru have teamed up to create a maternal health project, creating new maternal waiting houses ‘Mamawasi’ in order to address problems posed by geographic distance from health services. Peru currently has some 400 Mamawasi, mostly in the highland regions, all of which are operated by local health centres or hospitals.

Other positive developments include the January 2009 introduction of stricter phytotherapeutics regulations. As South America is rich in diverse flora, the successful harnessing of biological compounds can boost the local pharmaceutical industry. The new rules are expected to create a biodiversity list or framework, which will include all of the traditional medicines used by the native population, as well as provide legal protocols for pharmaceutical firms that may be interested in finding new drugs from biomatter. Moreover, illustrating Peru’s increasing attractiveness for foreign research companies, clinical research organisation (CRO) Parexel recently opened a base in Peru's capital, Lima.

Peru Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Read about our other Pharmaceuticals & Healthcare Reports

Africa

Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe

Asia

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam

Caribbean

Puerto Rico

Europe

Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan

Latin America

Argentina, Brazil, Chile, Colombia, Mexico and Venezuela

Middle East

Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates

North America

Canada and United States
Business Monitor International Business Monitor International
A Market Leader in Country Risk, Industry Intelligence and Company Research

Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK

BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world.

Country Risk Analysis and Forecasts
BMI
has for 25 years specialised in political risk analysis, financial markets analysis, and macroeconomic forecasts on 175 global markets.

Industry Intelligence and Market Research
BMI's industry research covers Automotives; Banking; Chemicals; Defence & Security; Food & Drink; Freight Transport; Information Technology; Infrastructure; Insurance; Mining; Oil & Gas; Petrochemicals; Pharmaceuticals & Healthcare; Power; Telecommunications, and Tourism.

Company Research
BMI maintains a fully-researched 55,000-site database of multinational company subsidiaries located across global markets.